Specific to individual cancer types, LUAD and LUSC have relatively high Hub-EGFR.Sig scores among cancers, and ample evidence has confirmed that EGFR tyrosine kinase inhibitors indeed prolong the PFS of NSCLC patients (94, 95). The gene discussed is EGFR; the disease is cancer.